Literature DB >> 24279938

Memory deficits in aged cebus monkeys and facilitation with central cholinomimetics.

R T Bartus1, R L Dean, B Beer.   

Abstract

Cebus monkeys of 3 different age groups were trained to perform an automated behavioral task (delayed response), intended to measure recent memory ability. In in initial study, the aged monkeys (18 years and older) exhibit prprogressively greater performance impairments (relative to young monkeys) as they were required to remember the location of a visual stimulus for increasingly longer durations (0 to 20 sec). This deficits replicated previously published results from aged Rhesus monkeys and appeared similar to the primary memory deficits reported in elderly humans and demented patients. In subsequent studies, the effects of three different cholinomimetics were evaluated for their ability to improve the aged monkey's performance on this task. Each monkey was tested under several acute doses of the cholinergic precursor, choline, the anticholinesterase, physostigmine, and the cholinergic muscarinic receptor agonist, arecoline. The results revealed clear differences in the ability of these drugs to improve performance on this task. Choline exerted no apparent effects in the aged monkeys at any dose tested. Physostigmine clearly enhanced performance in certain aged monkeys, but the optimal dose varied dramatically between subjects, replicating previously published results with aged Rhesus monkeys and humans. Arecoline produced clear improvement within a restricted dose range, with little variation in optimal dose between subjects. In addition to demonstrating differences in the effects of different cholinomimetics on memory performance in aged primates, these data also suggest a possible rationale for future investigations. Assuming that each of these drugs primarily affected cholinergic function in the manner conventionally attributed, these data suggest that, within the cholinergic system, the more directly one stimulates the receptor, the more one might expect robust and consistent effects on memory performance in aged subjects.

Entities:  

Year:  1980        PMID: 24279938     DOI: 10.1016/0197-4580(80)90008-1

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  14 in total

1.  Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway.

Authors:  M E Bach; M Barad; H Son; M Zhuo; Y F Lu; R Shih; I Mansuy; R D Hawkins; E R Kandel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

Review 2.  Nonhuman primate models of Alzheimer-like cerebral proteopathy.

Authors:  Eric Heuer; Rebecca F Rosen; Amarallys Cintron; Lary C Walker
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  Effects of chronic treatment with a cyclic AMP-selective phosphodiesterase inhibitor, rolipram, on excitatory amino acid neurotransmission systems in young and aged rat brains.

Authors:  H Kato; T Araki; T Chen; X H Liu; T Hiranuma; K Murase; Y Itoyama; K Kogure
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

4.  Behavioural tolerance to arecoline in rats: cross-tolerance to oxotremorine and prevention by pretreatment with atropine.

Authors:  D H Overstreet; O S Jamal
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

5.  Cholinergic modulation of memory in rats.

Authors:  V Haroutunian; E Barnes; K L Davis
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

6.  Memory enhancement: supra-additive effect of subcutaneous cholinergic drug combinations in mice.

Authors:  J F Flood; G E Smith; A Cherkin
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

7.  Enhancing effects of Hoe 175 on memory in mice.

Authors:  F J Hock; J L McGaugh
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

8.  Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's disease.

Authors:  T T Soncrant; K C Raffaele; S Asthana; A Berardi; P P Morris; J V Haxby
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  Functional and neurobiological similarities of aging in monkeys and humans.

Authors:  M L Voytko
Journal:  Age (Omaha)       Date:  1997-01

10.  Age-related changes in brain histamine.

Authors:  I M Mazurkiewicz-Kwilecki; G D Prell
Journal:  Agents Actions       Date:  1984-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.